Yes, HIDA scans are safe for the vast majority of adults and children, and the main safety concern is far smaller than most patients assume. A standard HIDA scan delivers roughly 2 to 3 millisieverts (mSv) of radiation, about the same as one year of natural background exposure in the United States, or 20 to 30 chest X-rays. Serious allergic reactions to the injected tracer occur in well under 1 percent of patients. The real exclusions are narrow: pregnancy, breastfeeding without a short pumping pause, and a handful of biliary or medication conditions that can distort results rather than cause harm.
What a HIDA Scan Actually Does Inside the Body
HIDA stands for hepatobiliary iminodiacetic acid. The scan is a nuclear medicine study of the liver, gallbladder, and bile ducts. A technologist injects a small amount of a radioactive tracer into a vein. The tracer binds to a carrier protein in your blood, travels to the liver, and is taken up by liver cells called hepatocytes.
From there the tracer is excreted into bile, the same way bilirubin and bile salts are. It flows through the bile ducts into the gallbladder, concentrates there, and then moves into the small intestine when the gallbladder contracts. A gamma camera tracks the tracer's position over 60 to 90 minutes. In plain terms: the scan watches your biliary plumbing work in real time.
This mechanism explains both the safety profile and the limits. The tracer is not a dye and does not stain tissue. It is a radiolabeled molecule, usually technetium-99m mebrofenin in the United States. The radioactive tag has a physical half-life of about 6 hours and emits mostly gamma rays, which exit the body rather than lingering. More than 90 percent of the tracer clears through the biliary system and gut within 24 hours.
Radiation Dose Compared With Other Common Studies
The dose is the number patients worry about most, and it deserves precise context. A typical HIDA scan uses 3 to 5 millicuries of technetium-99m, producing an effective dose of roughly 2 to 3 mSv. The gallbladder receives the highest local dose. For perspective, a CT scan of the abdomen delivers about 8 to 10 mSv, and a single chest CT is around 7 mSv.
| Study | Typical effective dose (mSv) | Rough equivalent in chest X-rays |
|---|---|---|
| HIDA scan | 2–3 | 20–30 |
| Abdominal CT | 8–10 | 80–100 |
| Chest CT | 6–8 | 60–80 |
| Coronary angiography | 5–7 | 50–70 |
| Natural background, one year (US average) | about 3 | about 30 |
| Dental X-ray (single) | 0.005 | under 1 |
One reconciliation worth stating plainly: the annual natural background in the US averages about 3 mSv per the National Council on Radiation Protection and Measurements, so a HIDA scan at 2 to 3 mSv sits at roughly one year of background, not a lifetime. The widely quoted "one year of background" shorthand is accurate only at the upper end of the HIDA range.
The cancer risk from a single 2 to 3 mSv exposure is statistically too small to measure in individuals. Radiation protection bodies estimate excess cancer risk at about 5 percent per sievert of dose using the linear no-threshold model, which would put a 3 mSv HIDA scan at roughly 0.015 percent added lifetime risk. That figure is a modeling estimate, not an observed outcome, and it is dwarfed by baseline lifetime cancer risk of roughly 40 percent in the US.
How the Tracer Becomes a Safety Question: Mechanism and Rare Reactions
Most HIDA safety discussion centers on the injection, not the radiation. Anaphylaxis to technetium-99m labeled agents is rare, reported in case reports and small series rather than large trials. Estimates from nuclear medicine adverse event registries put severe immediate hypersensitivity at well under 0.1 percent of administrations. Mild reactions such as flushing, hives, or a metallic taste are more common but still uncommon.
The molecule itself is biologically inert at the microgram doses used, so there is no pharmacologic toxicity. The safety question is therefore mostly about the radioactivity and the rare immune response, not a drug effect. A technologist will screen you for prior reactions to contrast or radiopharmaceuticals before injection.
A non-obvious mechanism: the tracer competes with bilirubin for the same liver uptake pathway. That means in patients with very high bilirubin, the liver may take up too little tracer for a readable image, so the scan can fail technically without causing any harm. This is a diagnostic limitation that patients often misread as a safety problem.
Who Should Not Have a HIDA Scan: Edge Cases and Timing
Pregnancy is the clearest exclusion. Fetal radiation exposure at 2 to 3 mSv is low but avoidable, and the American College of Radiology rates HIDA as generally not appropriate in pregnancy unless the benefit clearly outweighs risk. Breastfeeding is not a hard stop, but guidance suggests pumping and discarding milk for roughly 4 to 12 hours after injection, depending on the tracer, to reduce infant exposure.
Other edge cases matter more for accuracy than safety:
- Severe acute cholecystitis or suspected bile duct obstruction, where the scan may be technically limited and ultrasound or MRCP is preferred first
- Prior cholecystectomy, where the tracer has no gallbladder to fill
- Very high bilirubin, which can prevent adequate liver uptake
- Recent opioid use, which can cause false-positive gallbladder nonvisualization
- Glucagon, atropine, or certain calcium channel blockers, which alter gallbladder contraction
The opioid point is counterintuitive. Morphine increases sphincter of Oddi tone, and some patients show a falsely nonvisualized gallbladder that mimics acute cholecystitis, per a well-documented phenomenon described in the nuclear medicine literature. This is a diagnostic trap, not a safety risk, but it leads to repeat scans and unnecessary worry.
What Happens During and After the Scan: A Timeline
| Timepoint | What happens | What you may feel |
|---|---|---|
| Before injection | Screening for pregnancy, allergies, medications | Nothing |
| 0 minutes | IV tracer injection, imaging begins | Brief cool sensation in the arm |
| 0–60 minutes | Continuous or interval gamma camera imaging | Lying still, no discomfort |
| 60 minutes | If gallbladder not seen, morphine or cholecystokinin may be given | Mild abdominal cramping possible |
| 60–90 minutes | Additional imaging to assess ejection fraction | Nothing |
| Up to 4 hours | Extended imaging in some protocols | Waiting, no symptoms |
| 24 hours | Tracer clears through stool and urine | Nothing |
| 1–2 days | Drink extra fluids to speed clearance | Nothing |
The gallbladder ejection fraction (GBEF) calculation is the last part of many studies. A normal ejection fraction is generally 35 to 38 percent or higher after cholecystokinin stimulation; lower values suggest gallbladder dyskinesia. That threshold varies between labs, so a 35 percent cutoff at one center might be 38 percent at another.
Are HIDA Scans Safe for Children and Older Adults?
Pediatric dosing follows weight-based adjustment. Children receive proportionally smaller activities, often 0.05 to 0.1 millicurie per kilogram, which keeps effective dose in the same low range as adults. The same pregnancy and allergy screening applies. Children tolerate the injection well, and the scan requires holding still, which may need distraction or, rarely, sedation in very young patients.
Older adults carry the same dose but often more competing diagnoses. A HIDA scan in an 80-year-old with atypical symptoms can help distinguish biliary pain from other causes, and the risk profile does not change with age. The main caveat is polypharmacy, since opioids and anticholinergics can alter gallbladder emptying and confound the ejection fraction.
Common Misconceptions About HIDA Safety
One common claim is that the radioactive tracer stays in the body for years. It does not. Technetium-99m has a 6-hour physical half-life and about 90 percent or more clears within 24 hours through bile and stool. Residual activity is negligible within a few days.
Another misconception is that HIDA scans cause kidney damage the way iodinated contrast can. They do not. The tracer is handled by the liver and biliary system, not filtered by the kidneys, so there is no contrast-induced nephropathy risk. That makes HIDA a reasonable option in patients with kidney impairment who need biliary imaging.
A third claim is that the scan is unnecessary because radiation is "too high." At 2 to 3 mSv, it is lower than an abdominal CT and comparable to a year of background exposure. The risk-benefit calculation favors the scan when it answers a clinically important question, such as whether the gallbladder is obstructed.
What to Actually Do Before and After a HIDA Scan
Concrete steps reduce both risk and repeat imaging:
- Tell the scheduling team if you are pregnant or could be, before the appointment.
- Disclose all medications, especially opioids and anticholinergics, since they can affect results.
- Report any prior reaction to contrast or radiopharmaceuticals at check-in.
- If breastfeeding, ask the nuclear medicine team for the tracer-specific pumping interval.
- Drink extra water after the scan to help clear the tracer through stool and urine.
- Keep follow-up imaging decisions with your referring clinician rather than self-interpreting a low ejection fraction.
Limitations of the Evidence and When to Reconsider
The strongest safety data comes from decades of nuclear medicine use and adverse event registries, not large randomized trials. Rare hypersensitivity estimates rest on case reports and registry counts, so the true incidence is uncertain. The radiation risk figures are models, not measured individual outcomes. That means the confidence is high for the broad safety claim but lower for exact numbers at the extremes.
If you have severe acute illness, very high bilirubin, or an alternative study that answers the question faster, discuss whether HIDA is the right first test. Safety and accuracy are different questions, and the safest scan is the one that actually answers your clinical question.